Cargando…
P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429202/ http://dx.doi.org/10.1097/01.HS9.0000849696.81993.90 |
| _version_ | 1784779364962926592 |
|---|---|
| author | Gordon, L. I. Hoda, D. Shi, L. Guo, S. Liu, F. F. Braverman, J. Dubowy, R. Peng, L. Sehgal, A. |
| author_facet | Gordon, L. I. Hoda, D. Shi, L. Guo, S. Liu, F. F. Braverman, J. Dubowy, R. Peng, L. Sehgal, A. |
| author_sort | Gordon, L. I. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429202 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292022022-08-31 P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY Gordon, L. I. Hoda, D. Shi, L. Guo, S. Liu, F. F. Braverman, J. Dubowy, R. Peng, L. Sehgal, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429202/ http://dx.doi.org/10.1097/01.HS9.0000849696.81993.90 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Gordon, L. I. Hoda, D. Shi, L. Guo, S. Liu, F. F. Braverman, J. Dubowy, R. Peng, L. Sehgal, A. P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY |
| title | P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY |
| title_full | P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY |
| title_fullStr | P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY |
| title_full_unstemmed | P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY |
| title_short | P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY |
| title_sort | p1710: lisocabtagene maraleucel (liso-cel) as second-line treatment for r/r large b-cell lymphoma (lbcl) in patients not intended for hsct: patient-reported outcomes (pro) from the phase 2 pilot study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429202/ http://dx.doi.org/10.1097/01.HS9.0000849696.81993.90 |
| work_keys_str_mv | AT gordonli p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT hodad p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT shil p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT guos p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT liuff p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT bravermanj p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT dubowyr p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT pengl p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy AT sehgala p1710lisocabtagenemaraleucellisocelassecondlinetreatmentforrrlargebcelllymphomalbclinpatientsnotintendedforhsctpatientreportedoutcomesprofromthephase2pilotstudy |